Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2016 1
2018 1
2019 2
2020 3
2021 4
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Mauz-Körholz C, et al. Among authors: cepelova m. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9. Lancet Oncol. 2022. PMID: 34895479 Free PMC article. Clinical Trial.
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.
Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Mauz-Körholz C, et al. Among authors: cepelova m. Lancet Oncol. 2023 Mar;24(3):252-261. doi: 10.1016/S1470-2045(23)00019-0. Lancet Oncol. 2023. PMID: 36858722 Free article. Clinical Trial.
Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma.
Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, Wohlgemuth WA, Mauz-Körholz C, Körholz D, Kluge R, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Attarbaschi A, Ceppi F, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Moellers M, Buerke B, Stoevesandt D. Franke FC, et al. Among authors: cepelova m. Pediatr Blood Cancer. 2023 Aug;70(8):e30421. doi: 10.1002/pbc.30421. Epub 2023 May 27. Pediatr Blood Cancer. 2023. PMID: 37243889
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group.
Daw S, Hasenclever D, Mascarin M, Fernández-Teijeiro A, Balwierz W, Beishuizen A, Burnelli R, Cepelova M, Claviez A, Dieckmann K, Landman-Parker J, Kluge R, Körholz D, Mauz-Körholz C, Wallace WH, Leblanc T. Daw S, et al. Among authors: cepelova m. Hemasphere. 2020 Jan 10;4(1):e329. doi: 10.1097/HS9.0000000000000329. eCollection 2020 Feb. Hemasphere. 2020. PMID: 32072145 Free PMC article. Review.
Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL).
Kewitz-Hempel S, Kurch L, Cepelova M, Volkmer I, Sauerbrey A, Conrad E, Knirsch S, Pöpperl G, Steinbach D, Beer AJ, Kramm CM, Sahlmann CO, Erdlenbruch B, Reinbold WD, Odparlik A, Sabri O, Kluge R, Staege MS. Kewitz-Hempel S, et al. Among authors: cepelova m. Mol Imaging Biol. 2019 Dec;21(6):1182-1191. doi: 10.1007/s11307-019-01350-5. Mol Imaging Biol. 2019. PMID: 30945122
Prevention of activated brown adipose tissue on 18F-FDG-PET scans of young lymphoma patients: results of an ancillary study within the EuroNet-PHL-C2 trial.
Pötzsch C, Kurch L, Naumann S, Georgi TW, Sabri O, Stoevesandt D, Cepelova M, Körholz D, Mauz-Körholz C, Hasenclever D, Kluge R. Pötzsch C, et al. Among authors: cepelova m. Sci Rep. 2023 Dec 11;13(1):21944. doi: 10.1038/s41598-023-48871-2. Sci Rep. 2023. PMID: 38081864 Free PMC article. Clinical Trial.
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial.
Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Körholz D, Stoevesandt D. Kurch L, et al. Among authors: cepelova m. Pediatr Blood Cancer. 2021 Apr;68(4):e28903. doi: 10.1002/pbc.28903. Epub 2021 Feb 3. Pediatr Blood Cancer. 2021. PMID: 33538093 Free article. Clinical Trial.
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge R, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D. Kluge R, et al. Among authors: cepelova m. J Nucl Med. 2021 Mar;62(3):338-341. doi: 10.2967/jnumed.120.247924. Epub 2020 Aug 6. J Nucl Med. 2021. PMID: 32764122 Free article.
Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.
Stoevesandt D, Ludwig C, Mauz-Körholz C, Körholz D, Hasenclever D, McCarten K, Flerlage JE, Kurch L, Wohlgemuth WA, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlén J, Cepelová M, Klekawka T, Attarbaschi A, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Steglich J. Stoevesandt D, et al. Among authors: cepelova m. Pediatr Radiol. 2024 Jan 31. doi: 10.1007/s00247-024-05859-y. Online ahead of print. Pediatr Radiol. 2024. PMID: 38296856
15 results